检索结果 - Yi‐Long Wu

Refine Results
  1. 1
    Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China

    Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China 由 Yi‐Long Wu, Lan-ying Gou

    出版 2014
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    Immunotherapy in the Asiatic population: any differences from Caucasian population?

    Immunotherapy in the Asiatic population: any differences from Caucasian population? 由 Lun-Xi Peng, Yi‐Long Wu

    出版 2018
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  3. 3
    Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

    Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China 由 Si‐Yang Maggie Liu, Yi‐Long Wu

    出版 2017
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  4. 4
    Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)

    Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC) 由 Si‐Yang Maggie Liu, Yi‐Long Wu

    出版 2020
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  5. 5
    The resistance mechanisms and treatment strategies for <i>EGFR</i>-mutant advanced non-small-cell lung cancer

    The resistance mechanisms and treatment strategies for <i>EGFR</i>-mutant advanced non-small-cell lung cancer 由 Wen‐Zhao Zhong, Qing Zhou, Yi‐Long Wu

    出版 2017
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  6. 6
    The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer

    The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer 由 Yi-Chen Zhang, Qing Zhou, Yi‐Long Wu

    出版 2017
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  7. 7
    Overcoming immune evasion with innovative multi-target approaches for glioblastoma

    Overcoming immune evasion with innovative multi-target approaches for glioblastoma 由 Hai Su, Peng Yin, Yi‐Long Wu, Xiaoli Zeng

    出版 2025
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  8. 8
    Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

    Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) 由 Simon Dearden, James Stevens, Yi‐Long Wu, David P. Blowers

    出版 2013
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  9. 9
    Differences in driver genes between smoking‐related and non–smoking‐related lung cancer in the Chinese population

    Differences in driver genes between smoking‐related and non–smoking‐related lung cancer in the Chinese population 由 Lan-ying Gou, Feiyu Niu, Yi‐Long Wu, Wen‐Zhao Zhong

    出版 2015
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  10. 10
    Emerging therapies for non-small cell lung cancer

    Emerging therapies for non-small cell lung cancer 由 Chao Zhang, Natasha B. Leighl, Yi‐Long Wu, Wen‐Zhao Zhong

    出版 2019
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  11. 11
    LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer

    LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer 由 Zhongbao Zhang, Jiajing Cheng, Yi‐Long Wu, Jin Qiu, Yi Sun, Xiaowen Tong

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

    ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection 由 Yi‐Long Wu, Roy S. Herbst, Helen Mann, Yuri Rukazenkov, Marcelo Marotti, Masahiro Tsuboi

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    195TiP: Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042

    195TiP: Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042 由 Tony Mok, Yi‐Long Wu, S. Sadowski, J. Zhang, Reshma Rangwala, Debra Kush, Gilberto Lopes

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894)

    P2.43: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894) 由 Gilberto Lopes, Yi‐Long Wu, S. Sadowski, Jin Zhang, Reshma Rangwala, Debra Kush, Tony Mok

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Influence of Curcumin on HOTAIR-Mediated Migration of Human Renal Cell Carcinoma Cells

    Influence of Curcumin on HOTAIR-Mediated Migration of Human Renal Cell Carcinoma Cells 由 Chang-Song Pei, Hongyan Wu, Fan-Tian Fan, Yi‐Long Wu, Cunsi Shen, Liqun Pan

    出版 2014
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer

    Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer 由 Wen‐Zhao Zhong, Xue‐Ning Yang, Jianling Bai, Jin‐Ji Yang, Christian Manegold, Yi‐Long Wu

    出版 2008
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  17. 17
    Multiple primary malignancies involving lung cancer

    Multiple primary malignancies involving lung cancer 由 Feng Li, Wen‐Zhao Zhong, Feiyu Niu, Ning Zhao, Jin‐Ji Yang, Hong‐Hong Yan, Yi‐Long Wu

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy

    Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy 由 Bruno Coudert, Tudor‐Eliade Ciuleanu, K. Park, Yi‐Long Wu, Giuseppe Giaccone, Wolfram Brugger, P. Gopalakrishna, Federico Cappuzzo

    出版 2011
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study)

    Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IU... 由 Saulius Cicėnas, Sarayut Lucien Geater, Petar Petrov, Yevhen Hotko, Gregory Hooper, Fan Xia, Nadejda Mudie, Yi‐Long Wu

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Emerging evidence and treatment paradigm of non-small cell lung cancer

    Emerging evidence and treatment paradigm of non-small cell lung cancer 由 Si‐Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, Si‐Yang Maggie Liu, Yangqiu Li, Yi‐Long Wu

    出版 2023
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:

检索工具: